GSK plc vs Heartflow Inc. Common Stock — how do they compare? GSK plc trades at $47.87 (market cap $92.78B), while Heartflow Inc. Common Stock trades at $49.44 (market cap $4.38B). The key difference: GSK plc is far larger — about 21.2× Heartflow Inc. Common Stock's market cap, and GSK plc pays a 3.92% dividend while Heartflow Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Heartflow Inc. Common Stock for 0 Days on average.
| GSK | HTFL | |
|---|---|---|
Market Cap | $92.78B | $4.38B |
Volume | 5,756,402 | 1,454,420 |
Sector | Health | Health |
52-Week High | $61.18 | $52.21 |
52-Week Low | $43.24 | $20.49 |
Typical Hold Time | 93 Days | 0 Days |
Enterprise Value | $112.77B | $4.24B |
Dividend Yield | 3.92% | — |
Signals from Pluang's Aura AI — not financial advice
GSK trades at $47.87, up 2.02% today, with a bearish technical signal despite recent earnings beats. The company shows strong profitability with 72.73% gross margins and 14.52% net income margin, supported by consistent revenue growth from $32.67B in 2025. Recent developments include a $750M cancer therapy acquisition and strategic focus on oncology expansion.
GSK presents a mixed outlook with solid fundamentals and strategic pipeline investments offset by technical weakness and patent cliff concerns. The stock offers value at 14.84 P/E but faces execution risks in oncology growth and HIV patent expirations. Analyst consensus leans cautious with 55% hold ratings.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →HeartFlow, Inc. develops AI-powered software that analyzes coronary CT angiography scans to build personalized 3D heart models for coronary artery disease diagnosis, including its FFRct Analysis, Plaque Analysis, and Roadmap Analysis tools.
Read more on HTFL →